Post by Halozyme, Inc.

Yesterday, Halozyme reported record full‑year 2025 results, highlighted by 38% total revenue growth to $1.4 billion and 52% royalty revenue growth to $868 million. This performance reflects the continued strength of ENHANZE®, the global expansion of partner launches, and the meaningful steps we took to broaden our drug delivery technology portfolio. In 2025, we advanced our long‑term strategy by completing the acquisitions of Elektrofi’s Hypercon™ technology and Surf Bio’s hyperconcentration technology, adding complementary capabilities that expand and diversify our future royalty opportunities. We also signed three new ENHANZE collaboration and licensing agreements and saw important new approvals and indications from our partners across the U.S., China, and Japan. Looking ahead, we are reiterating our 2026 financial guidance, reflecting another year of strong expected growth: • Total revenue: $1.71–$1.81B (up 22%–30%) • Royalty revenue: $1.13–$1.17B (up 30%–35%) • Adjusted EBITDA: $1.125–$1.205B (up 71%–83%) • Non‑GAAP diluted EPS: $7.75–$8.25 (up 87%–99%) With royalty revenue projected to exceed $1 billion in 2026 and a clear line of sight to more than $2 billion in total revenue by 2028, Halozyme is entering its next phase of growth with strong momentum, a broader portfolio, and a deep pipeline of new ENHANZE and Hypercon program starts. We remain focused on delivering sustainable long‑term value and are grateful to our partners, employees, and shareholders for their continued support. Additional info can be found here: https://lnkd.in/gu2Si-9e